A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma

Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2011.0038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Harborside Press, LLC

Related search

Rapamycin Suppresses Angiogenesis and Lymphangiogenesis in Melanoma by Downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 Expression

OncoTargets and Therapy
OncologyPharmacology
2019English

VEGF Receptor 1 (FLT1; VEGFR-1)

Science-Business eXchange
2013English

Targeted Therapeutics

Cell
BiochemistryGeneticsMolecular Biology
2011English

Novel Targeted Therapeutics for MEN2

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2018English

FGFR2-related Pathogenesis and FGFR2-targeted Therapeutics (Review)

International Journal of Molecular Medicine
MedicineGenetics
2009English

RNA-Targeted Therapeutics

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2019English

Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Homocysteine-Impaired Angiogenesis Is Associated With VEGF VEGFR Inhibition

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2012English

Temozolomide Nanoparticles for Targeted Glioblastoma Therapy

ACS Applied Materials & Interfaces
MedicineMaterials ScienceNanotechnologyNanoscience
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy